Samsung Biologics to acquire Switzerland's PolyPeptide Group in $1.8 billion all-cash deal
--------------------------------------------------------------------
Source: CNBC
Published: 2026-07-20 12:12 UTC+10:00
Section: General
Factuality Score: 100
Opinion Category: Neutral
Topics: Health, Asia, South Korea, Asia Pacific
--------------------------------------------------------------------
Snippet:
South Korea's Samsung Biologics said on Monday that it had made an all-cash bid of 1.46 billion Swiss francs ($1.8 billion) for Switzerland's PolyPeptide Group, which specializes in peptide-based active pharmaceutical ingredients.
--------------------------------------------------------------------